Skip to main content
Clinical Trials/NCT03621774
NCT03621774
Completed
N/A

Mobile-assisted Cognitive Behavioral Therapy for Negative Symptoms in Schizophrenia: An RCT

University of California, San Diego1 site in 1 country112 target enrollmentMarch 27, 2019

Overview

Phase
N/A
Intervention
Not specified
Conditions
Schizophrenia
Sponsor
University of California, San Diego
Enrollment
112
Locations
1
Primary Endpoint
Defeatist performance beliefs (target mechanism) using the Defeatist Performance Attitude Scale
Status
Completed
Last Updated
last year

Overview

Brief Summary

This randomized controlled clinical trial will test a combined group contact plus mobile CBT-informed skills training intervention targeting defeatist attitudes in consumers with schizophrenia in comparison to a supportive contact control group in order to change motivational negative symptoms linked to defeatist attitudes.

Detailed Description

The primary purpose of this project is to determine if mCBTn at the optimal dose from the R61 produces greater reduction in severity of defeatist attitudes than a supportive contact control group in consumers with schizophrenia spectrum disorders with persistent moderate-to-severe experiential negative symptoms. A second aim is to determine whether reduction in defeatist attitudes mediates improvement in experiential negative symptoms and psychosocial functioning in mCBTn. The third aim is to determine whether mCBTn increases pupil dilation and whether changes in pupil dilation (an objective psychophysiological biomarker of effort) are associated with changes in defeatist attitudes and negative symptoms. The final aim is to explore predictors of response to mCBTn, including device use and group session adherence, demographics, neurocognitive impairment, and negative and other symptom severity at baseline.

Registry
clinicaltrials.gov
Start Date
March 27, 2019
End Date
August 31, 2022
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Eric Granholm

Professor In Residence

University of California, San Diego

Eligibility Criteria

Inclusion Criteria

  • DSM-5 diagnosis of schizophrenia or schizoaffective disorder.
  • Meets prospective criteria for persistent moderate-to-severe experiential negative symptoms in at least two of the three CAINS Motivation and Pleasure domains (mean of 2 -moderate- or greater for items averaged within the Social, Work or Recreational domains) at the beginning and end of a 2-week evaluation phase.
  • Moderate-to-severe defeatist attitudes (DPAS \> 50).
  • ≥ 6th grade reading level on the Wide Range Achievement Test-4 Reading subtest (needed for reading treatment manual consumer workbook).
  • Clinically stable and stable on current medications (no changes within 3 months prior to enrollment and meeting all inclusion/exclusion criteria during longitudinal baseline evaluation at both week -2 and 0).

Exclusion Criteria

  • Prior CBT in the past 2 years.
  • Greater than moderate PANSS positive symptoms (P1-Delusions, P2- Disorganization, P3-Hallucinations, or P6-Suspiciousness - any item \>5).
  • Severe depression on the Calgary Depression Scale for Schizophrenia (CDS \>8).
  • Extrapyramidal symptoms.
  • Ocular damage, disease, surgery or medications that affect pupil dilation.
  • DSM-5 alcohol or substance use disorder in past 3 months.
  • Level of care required interferes with outpatient skills training (e.g., hospitalized; severe medical illness).
  • Unable to adequately see or manually manipulate the mobile device.

Outcomes

Primary Outcomes

Defeatist performance beliefs (target mechanism) using the Defeatist Performance Attitude Scale

Time Frame: Assess change from baseline in defeatist performance beliefs at weeks 9, 18, and 42.

Measure changes in defeatist performance beliefs severity using the Defeatist Performance Attitude Scale (DPAS). The DPAS is a 5-minute, 15-item self-report subscale derived from factor analysis of the commonly-used 40-item Dysfunctional Attitude Scale, which measures the tendency to overgeneralize from past failure experiences and form defeatist beliefs about the ability to perform future goal-directed tasks. Items are rated on a 1-7 Likert scale. A total score is reported with a range of 7 - 105 with higher total scores indicating more severe defeatist performance attitudes.

Clinical Assessment Interview for Negative Symptoms (CAINS)

Time Frame: Assess change from baseline in negative symptoms at weeks 9, 18, and 42.

Measure changes in motivational negative symptoms on the CAINS. The CAINS is a 13-item interview-based assessment of negative symptoms, and each item is rated from 0 (no impairment) to 4 (severe deficit) measuring the two negative symptom factors recommended in consensus reports: Expression and Motivation and Pleasure (MAP) across social, vocational and recreational domains. Total scores for each factor are computed. The range for the MAP is 0 - 36, and the range for the Expression factor is 0 - 16. Higher scores indicate more severe negative symptoms for both factors.

Secondary Outcomes

  • Pupillary responses as effort biomarker(Assess change from baseline in pupil dilation at weeks 9, 18, and 42.)
  • Birchwood Social Functioning Scale (SFS)(Assess change from baseline in functioning at weeks 9, 18, and 42.)

Study Sites (1)

Loading locations...

Similar Trials